⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PLRX News
Pliant Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
PLRX
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
globenewswire.com
PLRX
Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board
prnewswire.com
PLRX
Form 8-K
sec.gov
PLRX
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
globenewswire.com
PLRX
Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
globenewswire.com
PLRX
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
globenewswire.com
PLRX
Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting
globenewswire.com
PLRX
Form 8-K
sec.gov
PLRX
Pluristyx Extends Patent Portfolio in Universal Cell Therapy with New U.S. Patent for iACT Stealth™ Technology
globenewswire.com
PLRX